Is Halozyme Therapeutics, Inc. overvalued or undervalued?

As of 13 May 2025, the valuation grade for Halozyme Therapeutics, Inc. moved from expensive to fair. The company is currently fairly valued based on its financial metrics. The P/E ratio stands at 14, while the EV to EBITDA ratio is 10.96, and the PEG ratio is notably low at 0.22, indicating strong growth potential relative to its price.
In comparison to peers, Halozyme's P/E ratio of 13.48 and EV to EBITDA of 10.76 are competitive, suggesting it is on par with industry standards. Notable peers include companies with similar financial profiles that reinforce this valuation perspective. Despite recent underperformance against the S&P 500 over the past month, with a return of -3.19% compared to the index's 3.83%, the long-term growth reflected in a 106.09% return over the past five years suggests a solid investment outlook.